Last updated: February 15, 2026
What Is the Market Status and Price Outlook for NDC 51079-0572?
NDC 51079-0572 corresponds to Ruxolitinib (brand name Jakafi), commonly used in treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. This drug is marketed by Incyte Corporation.
Market Overview
Marketed Indications:
- Myelofibrosis (primary and secondary)
- Polycythemia vera refractory to hydroxyurea
- Essential thrombocythemia (off-label/in clinical trials)
Competitive Landscape:
- Ruxolitinib is the only FDA-approved JAK1/2 inhibitor for the aforementioned indications.
- Competing products include Fedratinib (Inrebic) for myelofibrosis, which entered the market in 2019.
- The market is characterized by high unmet needs for treatment options and long-term management, supporting steady demand.
Market Size & Demand:
- The global myelofibrosis market was valued at approximately USD 800 million in 2022, with Ruxolitinib accounting for around 70% of sales in this segment (source: IQVIA).
- The polycythemia vera market is smaller but growing, with the overall hematology-oncology market driven by increasing diagnoses, especially in aging populations.
- Incyte reported product sales of USD 2.4 billion in 2022, with Ruxolitinib contributing approximately USD 1.7 billion.
Market Dynamics & Growth Drivers:
- Growing awareness and diagnosis rates.
- Extended indications, including ongoing clinical trials for psoriasis and graft-versus-host disease.
- Patent exclusivity until 2026, with potential for extensions or patent disputes.
Price Projections (Based on Current Pricing and Market Trends)
Current Wholesale Acquisition Cost (WAC):
- Approximate WAC for Ruxolitinib (Jakafi) is USD 11,000–USD 13,000 per month per patient, translating to an annual cost of USD 132,000–USD 156,000.
- Price varies based on dosage, treatment duration, and patient insurance/coverage.
Historical Price Trends:
- Since FDA approval in 2011, the list price has annually increased by 3–5% to cover inflation and R&D costs.
- No significant price discounts or mandatory reforms have affected the list price, although insurers and pharmacy benefit managers negotiate discounts.
Forecasts for 2023–2028:
- Prices are expected to remain stable or slightly increase (2–4%) due to inflation and market factors.
- Patent expiration in 2026 could lead to biosimilar entry, potentially reducing prices by 20–40% in the subsequent years.
- Market competition from Fedratinib may influence pricing strategies, possibly stabilizing or decreasing Ruxolitinib's price.
Price Influences and Regulatory Factors
- Patent laws and exclusivity: Patent expiry in 2026 opens the door for generics or biosimilar versions, likely reducing prices over time.
- Insurance Coverage: Payers negotiate rebates and discounts, often lower than list prices, influencing actual transaction prices.
- Global markets: Price varies significantly outside the United States, with prices generally lower in Europe and emerging markets.
Key Takeaways
- Ruxolitinib dominates its segment, accounting for the majority of R&D-driven revenue in hematologic malignancies.
- Market projections favor stable or slightly increasing prices until patent expiry, after which prices may decline significantly with biosimilar competition.
- Treatment costs are high, with annual patient costs exceeding USD 130,000, influenced by dosing and insurance negotiations.
- The evolving therapeutic landscape, including new entrants and expanded indications, could alter the competitive environment and pricing strategies.
Frequently Asked Questions
1. When is patent expiry for NDC 51079-0572?
The patent for Jakafi is scheduled to expire in 2026, opening opportunities for biosimilars and generics.
2. How might biosimilar entry impact prices?
Biosimilars could reduce prices by 20–40%, depending on market penetration and regulatory approval processes.
3. What are the primary factors driving Ruxolitinib's market growth?
Increasing diagnosis rates, expanding indications, and long-term management needs.
4. Are there regulatory or reimbursement policies influencing prices?
Yes; patent protections, insurance negotiations, and government pricing policies impact retail and wholesale prices.
5. What is the potential market size after biosimilar entry?
The market could contract but remain significant due to ongoing unmet needs and new indications.
Sources:
[1] IQVIA, 2022 financial reports.
[2] US Food and Drug Administration (FDA), approvals and patent data.
[3] Incyte Corporation annual filings.
